Laryngeal Carcinoma Recurrence Rate and Disease-free Interval are Related to CD105 Expression but not to Vascular Endothelial Growth Factor 2 (Flk-1/Kdr) Expression

• Published in: Anticancer research Vol. 28; no. 1B; pp. 551 - 557
• Main Authors: MARIONI, Gino, GIACOMELLI, Luciano, D'ALESSANDRO, Emiliano, STAFFIERI, Claudia, GUZZARDO, Vincenza, STAFFIERI, Alberto, BLANDAMURA, Stella
• Format: Journal Article
• Language: English
• Published: Attiki International Institute of Anticancer Research 01.01.2008
• Subjects: Aged; Antigens, CD - biosynthesis; Biological and medical sciences; Disease-Free Survival; Endoglin; Endothelial Cells - metabolism; Female; Humans; Immunohistochemistry; Laryngeal Neoplasms - enzymology; Laryngeal Neoplasms - metabolism; Laryngeal Neoplasms - pathology; Laryngeal Neoplasms - surgery; Male; Medical sciences; Neoplasm Recurrence, Local - enzymology; Neoplasm Recurrence, Local - metabolism; Neoplasm Recurrence, Local - pathology; Neoplasm Staging; Otorhinolaryngology. Stomatology; Receptors, Cell Surface - biosynthesis; Tumors; Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology; Vascular Endothelial Growth Factor Receptor-2 - biosynthesis; Laryngeal cancer; Larynx carcinoma; Relapse; Prognosis; vascular endothelial growth factor receptor 2 (VEGFR2); Malignant tumor; Fetal liver kinase 1; recurrence; Laryngeal carcinoma; Cancerology; Vascular endothelium growth factor; ENT disease; CD105; Larynx disease; Vascular endothelial growth factor receptor 2; Cancer
• ISSN: 0250-7005; 1791-7530

Background: Tumour angiogenesis is the result of an inbalance between anti- and pro-angiogenic factors. CD105 (endoglin) is a component of the receptor complex of transforming growth factor (TGF-β1). Vascular endothelial growth factor receptor 2 (VEGFR2 or Flk-1/KDR) belongs to the high-affinity VEGF receptors. The aim of the study was to investigate the expression, cellular localization and role of CD105 and VEGFR2 in laryngeal carcinoma. Patients and Methods: Sections of 62 laryngeal carcinomas were stained with CD105 and VEGFR2/Flk-1/KDR antibodies. Results: A significant association between CD105 expression and locoregional recurrence was found (p=0.009). Interestingly, in N0 patients CD105 expression was significantly associated with locoregional recurrence of the carcinoma (p=0.03). The log-rank test showed a significant difference in the disease-free interval in patients stratified according to CD105 expression (p=0.02). Statistical analysis showed no significant associations between vessel endothelial cell or laryngeal carcinoma cell VEGFR2 expressions and recurrence of disease or disease-free intervals. Conclusion: CD105 expression but not VEGFR2 expression correlated with carcinoma recurrence after treatment and shorter disease free interval. The CD105 expression may be useful to detect cervical node-negative patients with a higher risk of early laryngeal carcinoma recurrence.